Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Medicover, Audiocast, Q3'26

By Inderes11/4/2026, 8:30 AM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

John Stubbington
00:01 - 15:48

Good morning everybody. It is John speaking. Welcome to our Q3 results presentation. It is another consistent quarter where we have seen good growth and it is our seventh quarter of year-on-year margin improvement, which is something that we are really proud of, particularly as it is another challenging comparable quarter from the performance that we had a year ago. So that is pretty good. Let's just remind everybody that we made a decision to divest our business in India. That was a transaction valued at €1.2 billion. You can see that our shareholding of that is 66.1%, which means that we should receive funds of approximately 740 million, which is really good. And we expect that to close sometime in November, which is what we've communicated before. Or it will close in Q4. Medicover and local partners have sold 100%. So that is a complete exit for us. And that means that in this presentation, Most of the figures, unless otherwise stated, relate to continuing operations. So, that is what this implies. That is the way that we will deal with the communication. I don't think we should underestimate this achievement. We built a significant presence in India over the period that we were there. We are excited about the funds we will receive, as they will help us reshape the business for years to come. So it's exciting times for us. Let's focus back on the Q3 organic revenue growth of 8%. So it is a solid performance from us. We recorded a 2% negative FX impact. You can see EBITDA is up 22%. So that's really good movement for us. It continues a trend that we've established, which, of course, we are very proud of and very happy with. It also comes at a time where we are actually repurposing a lot of our facilities. And if you look back over the course of the last 12 months, we have actually closed 118 units. So we have been opening units at the same time, but closing a lot of units at the same time. And of course, as you close units, revenue decreases immediately, whereas as you open units. It takes a bit of time for that revenue to build. So that's in our mix and will continue to be in our mix for a while. Healthcare services revenue was solid, and our sports and wellness business has a consistent trend, which has carried on throughout the quarter. Our diagnostic services are performing very well, strengthening the fee-for-service revenue. As we all know, if you have a stronger fee-for-service revenue, you have more control over pricing. And you can see that leverage decreased over the quarter. Which is really good for us. So good revenue, good growth, a very positive movement on our adjusted EBITDA, as you can see, plus 7.1% and our margin is a pleasing trend, taking us from 17.6% to 17.8%, with a healthy cash flow. And as I say, leverage is down. If we look at the revenues across the group and at this graph, it is slightly different than normal on the left-hand side where the light blue reflects the whole business. And as we go to the darker blue, we start to look at the continuing business. So you can see the difference. We have performed well in terms of revenue, with growth of 6%. So still healthy growth for us. As you look at it by country, there is healthy growth in Poland; we have a bit of work to do when it comes to Germany and Romania, but we are well aware of that and have plans in place regarding revenue by payer. You can see we strengthened again in the fee-for-service payer, which is very positive for us for the reasons that I explained before. It is also our major payer, which means that people have a choice of who they use and who they decide to utilize. So if they're choosing us, that's always a good sign. You can see the governmental income is flat due to all the macro changes that we've talked about before, which we're managing. And it's nice to see, if you look at the revenue, that there's a plus 5% there. And we are doing a lot of work in that particular sector that is looking quite positive for us. If we look at healthcare services, organic growth of 8% with margin expansion. So, very good indeed. You see the revenue is up 6%, with price being approximately 6.3%. FX is 1.9%. Fee for service and other services performed well, which is good. Sports and wellness, as we discussed previously, has been strong and we continue to open facilities. And I think we'll be accelerating that, not only in Q4 but beyond, as members in Poland grew. So, Poland had an increase in members, and regarding Romania, we talked about that last quarter in terms of some of our account management. So we're seeing the adjustments that occur there. And then our ongoing relationships with customers that are either paying us regularly or they're part of our loyalty schemes, etc. . We are building that consistently. You can see that is 4.1 million people now from 3.6 in revenue. We have discussed our revenue by country. Poland. Healthy. You can see the results in the other countries. That is mainly due to the repurposing of the property. And Romania relates to the membership. EBITDA margin is very good. You can see 19.1% to 19.8%. So we are very pleased about that. And I am happy for the team. We have a really strong membership base at 1.5 million, and revenue by payer is increasing. You can see each one of them is up. That is really good for diagnostic services, with really solid FFS growth. So we explained the importance of that earlier in my conversation. Revenue is pleasing and consistent. You can see quite a bit of that is coming from price. And that shows the strength of our fee-for-service, very consistent in terms of building the FFS revenues in this area. Germany was a little bit softer this quarter. We believe that's a temporary position due to some of the vacation patterns that occurred and some lower activity that should come back. We continue to increase our BDPs, particularly in Poland. We want to strengthen our position here. Lab tests are up, so it is very solid and very consistent. You can see the revenue is up 6.3%, very steady, with a slight change in the margin. But again, we think we can manage that over time. Test increase is pretty good in terms of revenue by country. It's all up. And if you look at the payer mix, it is a much stronger mix. And that's a trend that's been happening for quite a period of time. So all credit to the team. That should strengthen our position. We've added one extra slide for you related to some exciting developments that we have with our Medicover Genetics team. We want to give you more detail on our MRD product launch. It is an exciting time for them. Basically, we have a simple blood test that detects early signs of lung cancer returning. So, when a patient has their treatment, the traditional method for clinicians to be able to see if the cancer has returned involves scans and testing. And they have received the clear scans and testing. But with this, the blood test can be done much earlier and much more simply because it does not rely on there being tumor tissue to search for. So it is blood-based, which means that we can do monitoring earlier and actually do it more frequently. And the indications are that it picks up if there is an issue 7.4 months earlier. And of course, this is all evidence-based. It's a methodology we think can transfer to other areas, so we can expand it. And we have actually launched this product now. So we wanted to signpost this to really get the word out that we have made this development. We have worked on it for a long period of time. We have mentioned it before, but we really wanted to get it out there. So I will now hand over to Anand, who will talk through some of the financials in a bit more detail. Over to you. Thank you, John, and good morning, everyone. In summary, I would say another solid quarter from us with good organic growth and margin accretion year-on-year. John mentioned that our total revenues were up 6% with organic revenues up 8%. Bear in mind that's on a continuing basis. As John mentioned, most of the numbers in this slide are based on a continuing basis. If you look on a total basis for a comparator to Q2, our total revenues would be up 8% and our organic revenues will be double digit in terms of performance from a profitability perspective. There was good flow-through from the revenue numbers into our profit. So EBITDA in particular, you can see at 49.3 million. That resulted in margin rate improvement of 110 basis points year-on-year, which is very good. And EBITDAaL, which is our cash profit, is a metric we focus on very strongly. You can see there is good year-on-year growth to 70.9 million, with the rate up 70 basis points year-on-year. That naturally flows into a stronger EPS of just over 16 cents per share in terms of healthcare. Strong organic revenue growth of 8%, with price driving 6%. Good margin growth across all measures, I would say. So EBITDA is up 70 basis points year on year, and EBITDAaL is up 90 basis points year on year. From a medical cost ratio perspective, it is better in the quarter. That is masked by a mix shift toward scaling in our sports businesses. But still, the underlying medical cost ratios are strong. In terms of the business unit performances, John has mentioned it. We were strong in sports and ambulatory in Poland, slightly offset by hospitals in Poland and Romania. In terms of diagnostics. So good organic growth again of 8.5%, split roughly 50-50 between price and volume. From an EBITDA perspective, margins were flat year on year at 14.3%. And from an EBITDAaL perspective, margins were marginally down 20 basis points. That's largely due to softness in Germany and Medicover Genetics being offset by stronger performances in Poland, Romania, and the CEE. What we are doing, given the ongoing changes to reform in Q4, is taking action. So we took some action in Q3 and we will take further actions in Q4 to make sure we are in good shape for the changes in 2027. In terms of other financial metrics, as EBIT grows, our balance sheet remains broadly stable. Our leverage is decreasing, which is positive. So down to 2.7x, our ROIC is up from the start of the year to 14% from 13%. Effective tax rate of 28% for the quarter. I mentioned previously that we will be between 26% and 30% for the year. That remains the case. From a cash flow perspective, there is a bit of a timing issue. So still strong cash generation. Let's be honest. There is strong profit flowing into the business. But there is a bit of timing in Q3 from a cash flow perspective. Some of it is in the base from last year, and some of it will revert in Q4. So overall, I think it is pretty strong, pretty solid in terms of other metrics. Moving to the usual CAPEX slide. You can see to the left that there is still ample headroom between our free cash flow and our investment CapEx, which is good. On the right, you can see in terms of the percentage spend of revenue. So we spent 5.1% of revenues in Q3, largely 50/50 between maintenance and growth. Two-thirds of it is, as normal, on healthcare services and a third on diagnostics in terms of CapEx; for the full year, it will still be between 6% to 6.5%, as previously mentioned, in terms of medical space, broadly unchanged quarter-on-quarter at just over 1,000,000 m². And finally, from a target's perspective, we stand by the targets that we've set before for now. So we've had a strong year, a strong seven quarters. As John said. Until there is a call on the closure of the Medicover Hospitals India operation, we will be sticking with these targets. With that, I'll hand you back to John. Thanks. Key takeaways for us. It is a solid and consistent quarter. It has good growth in it. 8% organic revenue growth. EBIT is up 22%. I think quite an impressive movement from 7.5% to 8.6%. So, I think that is pretty good. FFS and sports and wellness drove quite a bit of the growth, and the acquisitions supported the synergies; the Indian divestment brings us 740 million, and we will focus that money on our core countries. We continue to focus on efficiency. It is really important in healthcare that you constantly generate that, make sure that our pricing is appropriate, and ensure we maintain cost control. I think there are three things we've talked about quite a bit over recent quarters. And I think you can see from the fact that we've managed our margins well, that that discipline is really in place. Public reimbursement is a near-term headwind. We've signaled some headwinds that are happening. We have signaled that before. We have a strong track record of signaling these things and then managing them over a short period of time. So we fully expect to do the same. It is exciting times for us. We have great opportunities due to the Indian transaction and all the work we are doing on our organic revenue growth. So we are looking forward to future quarters. And finally, as always, a big thank you to all the teams for producing these results. We really appreciate what you do, particularly our team in Ukraine, who obviously have had an even tougher time recently but still managed to do fantastically well. So thank you.

Operator
15:56 - 16:13

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Ekengren from Nordea. Please go ahead.

Philip Ekengren
16:15 - 16:41

Hello. Good morning, John Arnold. Let's start with Germany. Perhaps. Is it possible to quantify the margin impact or the potential margin impact from the reimbursement changes to German genetics? And how much do you think you realistically can offset during 2027. And perhaps also if you could just comment on how large genetics is of the diagnostic business. Thank you.

John Stubbington
16:43 - 17:49

Yeah. No problem whatsoever. That is a natural question to ask. In the way that the reform will come through, it is a little bit vague in terms of the mix of the exact impact on us. So it's more of a range. We would rather not comment on that at this stage and would prefer to go through the first quarter before providing a more detailed position. From the modelling that we have done, we fully expect to see it and we will feel it, but we fully expect to manage it over the course of the next four quarters. So as we go through, similar to what happened with the previous reform in Germany, we think we'll be able to handle it in a similar way, which is we'll see it to begin with. And as we go further into the quarters, we should be able to wash it through. In terms of size, we don't really disclose the exact position of Medicover Genetics for competitive reasons, but it is obviously not one of the largest businesses that we have in the group. If it were, it would be broken out and people would be able to see it.

Philip Ekengren
17:51 - 18:06

Makes sense. Thank you. And then just a follow-up on Germany perhaps in the quarter. During the call, it sounded quite temporary, but could you just elaborate a bit on what you saw during the quarter and what was impacting diagnostics in Germany?

John Stubbington
18:06 - 18:56

Yeah. I think we signaled there about the staffing patterns and different types of holidays. If you haven't got the doctors there, sometimes you don't get the tests and you don't get the consultations that occur. It just changes the mix a little bit, so it can happen. It frequently happens in Q1 and Q3 because you have holiday patterns and people decide to take different periods off. So, we expect all of that to regulate itself if you take a longer-term position. So, we will see as we go through Q4 what actually happened, because at the end of the day, doctors still need to treat patients to be able to drive their own personal revenues. And that therefore is reflected in our business. So it usually balances out.

Philip Ekengren
18:58 - 19:14

Thanks for that. And then perhaps moving on to healthcare services, 8% organic growth, with some 6% from pricing. What is holding back volume in this quarter? And how do you see that progressing into Q4 and into 2027?

John Stubbington
19:14 - 20:13

This is a reflection of previous quarters rather than the current quarter. If you remember, we have talked quite openly about our pricing position and the fact that the stance we took was price, not volume. We maintained this stance for a period of time. And we have discussed that we do need to change that. But remember, this is mainly in the B2B sector. B2B sectors are not a sector where the decision-making processes happen overnight. Yeah. It has a certain cycle to it. So we've made the changes we need to make to be able to stimulate our growth. The two markets where we operate in this segment, Poland and Romania, had slightly different starting points when we implemented those changes. But as you go through the full cycle of a B2B contract, we should be able to see some of that growth start to come through. And you know, we can see the pipeline or the beginnings of the pipeline. So we fully expect the B2B to start to move soon.

Philip Ekengren
20:15 - 20:17

Thank you, John. I'll get back into the queue. Thanks.

John Stubbington
20:17 - 20:19

No problem. Thanks a lot for the questions.

Operator
20:25 - 20:30

The next question comes from Julia Angeles from Handelsbanken. Please go ahead.

Julia Angeles
20:32 - 21:01

Hi. Thank you for taking my questions. My first question is on price contribution and more related to out-of-pocket payments. So, what are you seeing there? Are you seeing a softer dynamic? And perhaps also if you could specify what you mean by medium time frame or how far out that extends?

John Stubbington
21:03 - 22:50

Are you relating to the comments in the statement in terms of how long this will take to wash through? It is slightly different for the different lines depending upon the issue. So, if everyone wants context, I will provide it in one go, which is that when you look at our revenues, what is impacting us is that there are three things happening at a similar time. You've got the governments of each of the countries making different changes. You can see that with the question we just had on Medicover Genetics. You have the fact that we implemented location changes. You have 118 locations disappearing. And then the B2B subject that I have just talked about in terms of the timing and phasing that is related to it. Governmental changes, when they modify a contract, can sometimes take a full year before you come out the other end, which is what we just said about genetics, and location repurposing just washes through. It depends on when we started. It depends when we finished, but we have more openings that are going to happen than closures. So we should be in a different cycle. And then the membership matters I just discussed, and those three factors have a slight impact that builds up in this circumstance regarding fee-for-service. So for us, we signaled this before, and we actually came through it. Okay. A year ago and we actually came through those quarters. Okay. We are signaling again because those three things are present. It is appropriate for us to signal. And then you've got the German genetics change on top. We have washed these through. These troughs are temporary, but with some, it is one to two quarters. With some it's three or four.

Julia Angeles
22:54 - 23:14

Okay. Understood. I mean, aside from adapting to the market conditions, adjusting your offering, what is it? What would be a good way to utilize your market position in this environment? It is a good time to acquire and focus on taking market share.

John Stubbington
23:14 - 24:14

Well, I think we're in a really good place. I think we're in a really good place. We have a lot of organic development that is coming through in terms of some of our IT development and some of our consumer-based engagement tools. When the India transaction closes, as an organization, we should be debt-free. We are facing a world where it looks like interest rates are going to go up and governments are going to be adjusting their systems, which could impact some of our competitors and smaller players in terms of their ability to cope. So we're really well placed to take advantage of some of those dynamics. So whilst we are signaling concerning our revenues, our revenues are still strong. Revenues. Yes, they are still good revenues. But we are signaling that we will sort these problems out. We will be really well placed. So as a team, we are pretty confident.

Julia Angeles
24:16 - 24:35

Okay. And then just the last one for me, and sort of a follow-up to that. So I guess, given what you learned from this quarter and the performance this quarter, is there any area, segment, or geography that has given you more confidence in operations? Is there any area, segment, or geography that has given you more confidence in operations?

John Stubbington
24:36 - 25:35

We have confidence in a lot of our operations. So, just because you have a few issues; if you run, sorry, I will say it in a different way. If you run the type of business that we run, which is a portfolio of different companies, you will never have a position where everything is going perfectly, but you will always have a position where lots of things are going well. And of course, a lot of it is within the mix. So, we're feeling confident because we have lots of things that are going well. That is why our results are good. So we are very pleased with that. We have got some challenges, but we've also got a very experienced team that is used to dealing with those challenges, and we face an environment and a circumstance where we have a lot of choice due to the Indian transaction. So we are feeling pretty confident even though we are signaling some of the short-term issues that we have to manage. We have a history of managing these things, but it is appropriate for us to signal it.

Julia Angeles
25:36 - 25:40

Okay. I guess equally confident across all three core markets then.

Unknown 1
25:42 - 25:42

Yeah. I mean.

John Stubbington
25:42 - 25:58

They have different challenges. They might be, as we go through quarters looking ahead, that one of them goes stronger and one of them goes weaker for a period of time before we get there. But we have a history of being able to manage the things that come to us. So, we will see where we get to.

Julia Angeles
25:59 - 26:00

Okay.

Unknown 1
26:00 - 26:02

Thank you. Thanks a lot. Thanks for the question.

Operator
26:07 - 26:11

The next question comes from Jacob Anderson from Danske Bank. Please go ahead.

Jacob Anderson
26:13 - 26:25

Good morning, John and Anand. You talked a little bit about this, but could you perhaps clarify again what is driving the membership decline in Romania? Is it just general weak demand? And what are your actions to try to increase members going forward?

John Stubbington
26:26 - 27:29

Yeah, we talked about it last quarter if you remember. We made some decisions ourselves about some of the pricing. And we knew that some of the accounts would go for that. Obviously, there is the economic situation where organic, natural growth—where businesses are adding more employees—has slowed down a bit. The teams have reworked the product range in terms of finding new niches to be able to stimulate growth. Romania is a little bit further behind than Poland in terms of implementing changes and strategic initiatives. The stimulation, but we expect to see membership growth come back into our business even though it's a little bit more challenging in terms of some of the economic situation in Romania. So now, product ranges have been looked at. So I think that will help us as we go forward. As I said earlier, there is a pipeline and that pipeline is visible to the teams and it is stronger than it was. So it should come through.

Jacob Anderson
27:30 - 27:44

Yeah. Okay. Perfect. And what do you believe needs to change for the hospital margins in Poland and Romania to improve? And do you expect the pressure to continue into Q4 and at the beginning of next year, or how do you view it?

John Stubbington
27:44 - 28:34

The hospital situation may sound like doom and gloom, but it is actually driven by governmental changes. Yeah. And that affects your revenue mixes. They do not turn as fast if you have to change your operations. But we are changing our operations. If tariffs are changing or if mixes are changing to accommodate it, Romania does have a blending of governmental contracts with fee-for-service. Poland does not allow it. And you can see that, as a consequence of that, Poland's fee-for-service in hospitals is pretty strong. So it is pockets of issues that we just have to manage. There are elements of our hospitals that are still doing really well and are very strong.

Jacob Anderson
28:35 - 28:49

Yeah. Okay. And just lastly, on or within diagnostics. So which areas of advanced testing do you see the strongest growth, and how much can that mix improvement offset the weakness in Germany, would you say over the coming quarters?

John Stubbington
28:49 - 29:54

There is a significant trend in all countries related to lifestyle testing. People talk quite often about medical testing that comes from doctors, which is appropriate. But you don't have to do too much research to see longevity, and I think I've said it right for once. Longevity just keeps being talked about all the time. And lifestyle-related testing is directly related to that. You can actually start seeing that in the mix and you definitely see it in the narrative. And that is not necessarily traditional. I have a medical problem. I need to get a doctor to give me a test. This can be people wanting to look at different factors, for example, the strength of my nails and the strength of my hair, which is much more to do with the cosmetic side of life than it is to do with the medical side of life, although there is an element that is related. So there's lots of opportunity when it comes to the diagnostic side.

Jacob Anderson
29:56 - 29:59

Yeah. Okay. Perfect. No more questions for me.

Anand Patel
30:00 - 30:00

Okay.

Operator
30:04 - 30:10

The next question comes from Anna Salamon from ABG Sundal Collier. Please go ahead.

Anna Salamon
30:11 - 30:30

Thank you and good morning. I have a few questions. I'll start off with a question about India, and I'm not sure you can answer questions about capital allocation, but what might be the priorities for the proceeds of the deal and how soon after the close can we expect new targets?

Anand Patel
30:31 - 30:52

Yeah. So obviously, our focus at the moment is concluding the deal and we are all focused on doing that. In Q4, post-completion, management will obviously have a view, and we will have a discussion with our board. At the appropriate time, we will provide an announcement regarding our plans for the proceeds. But for now, let's just make sure we get the proceeds in. That's all we're focused on.

Anna Salamon
30:53 - 31:11

Yeah. Thank you. And regarding sport and wellness, what is the payback time on a new gym and how does the pure gym EBITDA margin look, and how many openings do you have planned for Q2 and Q4 2027?

John Stubbington
31:12 - 31:53

They are all very interesting questions that you have just asked, and they are all questions that our competition would love to know. Yeah. So it's unlikely that I'm going to answer those questions for you, but I feel it's always unfair not to answer a question a little bit. It is obviously a very positive financial impact that we have from that particular side of our business and if you look to each question that you asked, it probably grows faster than our core standard healthcare side. So it is accretive for us and it is very positive for us.

Anna Salamon
31:55 - 32:10

Okay. Thank you. And the last question, the member base fell 4%, driven mostly by Romania and weaker hospitals. Do you think this is a trend that might continue? Or do you expect this to stabilize in the following quarters?

John Stubbington
32:11 - 33:25

No, I mean, the organic growth from membership is slower. And that is an industry trend in both of the markets from which we have membership. And that is why we will look to stimulate other products to be able to get more growth coming through, which we've started, we are well advanced with it; we have some new products that are in place. We have some new products that are about to hit the market. It is also one of the reasons why we developed our sports segment, as that is an alternative membership base that we are building and expect to grow. As we mentioned previously, while it has been subdued by price and certain market dynamics showing slower growth, I believe our competition would value some parts of our proposition, such as sport and wellness. That allows us to be a little bit more flexible, dynamic, and creative when it comes to product development. So I think we're well placed when it comes to those market dynamics. And you should be able to see those results come through. Let's see.

Anna Salamon
33:27 - 33:29

Perfect. Thank you John.

John Stubbington
33:29 - 33:30

Thank you.

Operator
33:38 - 33:43

The next question comes from Christopher Lilleberg from ABG Sundal Collier. Please go ahead.

Christopher Lilleberg
33:45 - 33:57

Yeah. Hi. Good morning. I have five questions. I hope that's okay. First, could you say anything about the return on investments in India, how much you have invested or something like that?

Anand Patel
33:59 - 34:40

No, we haven't mentioned that. I think what we have said previously, as you know, is we've invested a disproportionate amount of capital in India over the past few years versus the total base of Medicover, I'd say. I think the other thing we shared when we did our last announcement was that the last 12 months' profit in India from an EBITDA perspective was about €26 million from memory, and we have secured an enterprise value of €1.2 billion. So, I am not going to give you exact numbers on return on investment, including the amount of equity we have put in, but we have invested a fair amount of capital. But it is a very strong return. Yeah.

Christopher Lilleberg
34:41 - 34:47

And that leads me to my next question. The CapEx slide you had, was that included or adjusted for India?

Anand Patel
34:50 - 34:55

Including. So India is about 10% of the business and will be about 10% of the CapEx.

Christopher Lilleberg
34:57 - 35:06

Okay. But so CapEx as a percentage of sales. I guess that should perhaps be lower. Going forward, excluding India?

Anand Patel
35:07 - 35:32

Yes. Yes, it should be. Yeah. But obviously, as we have been coming to the end of our journey with India, let's call it that, we have been reducing CapEx in India spend anyway. So I guided for the full year that it will be between 6% to 6.5% of revenues for total CapEx on a continuing basis. And that is what it will be roughly.

Christopher Lilleberg
35:34 - 35:40

And do you think that's a figure we should expect also for coming years?

Anand Patel
35:40 - 35:53

We will guide on coming years at the appropriate time for now. Historically, in the last couple of years, we've spent between 5% to 6.5%. So that's not an unreasonable assumption. But we're not guiding on 2026. Yes.

Christopher Lilleberg
35:54 - 36:14

Okay, great. And then coming back to Germany and the genetic business, of your total genetic business, how much of that is Germany? And within Germany, could you give some color, maybe on the public funding versus fee-for-service?

John Stubbington
36:15 - 36:54

Yeah. We do not disclose it. I think regarding the German business, we understand the need to model what will happen with that change. But actually a lot of it will depend upon the mix. And a lot of it will depend upon what happens in the market, because this change is quite, on face value, quite brutal. We will be able to ride it and come out the other end, but some people won't be able to ride it and come out the other end. So, I think that we will see quite a few little micro things that occur. So we are going to sit on this one and just wait until we go through Q3 and then we will give you more flavor.

Christopher Lilleberg
36:55 - 37:13

Okay. And the comments you made here about the reimbursement. Reimbursement and near-term pressure. Should we see that as a signal that organic revenue growth might be slower in the coming quarters than what we saw in the third quarter?

John Stubbington
37:14 - 37:37

We have decent growth in MHI. We might see some slight changes, but we have countermeasures in place. So it is there, and it may or may not happen. We will go through Q4 and see where we land. But those pressures are there. That is why we wanted to flag them.

Christopher Lilleberg
37:38 - 37:53

Yeah. But regarding those countermeasures, do you think they will help over the next one or two quarters as well? Or should we expect a more dramatic slowdown and then a pickup in, let's say, 3 to 4 quarters from now?

John Stubbington
37:54 - 38:01

That is a significant word. Yeah, yeah. I don't think that is a word that we have used, so I would not like to include it.

Christopher Lilleberg
38:01 - 38:03

I will rephrase it to somewhat instead.

John Stubbington
38:04 - 38:41

We are signaling this because it could happen; when you have countermeasures, the question is whether they will all come through on time in Q4 or not? Who knows? Let's see. Yeah, but we're not sitting here with any particular concern. We have still got good growth, strong business, and strong lines. There are a few things that we have to manage. So I wouldn't overly panic over the signaling, but the signaling should be there because those things are there. Yeah. And of course, the Medicover Genetics business will hit us. Medicover Genetics will impact our performance.

Christopher Lilleberg
38:42 - 38:57

Yeah. And sorry for all my questions. The last one here: would you say the lack of growth in Romania is an even mix between hospital, market, and liberal members?

John Stubbington
38:57 - 38:58

I think that is fair.

Christopher Lilleberg
38:58 - 39:10

Okay. Yeah. Okay. And is the lower number of members entirely due to Romania? The number of members grew in Poland, for example.

John Stubbington
39:10 - 39:26

Yeah. They did. I said earlier that in Q3 we had growth in Poland. It was small growth. We are still cycling out some of that price adjustment that we put through. But as I said before, I fully expect that as we go through a couple of quarters, you will see a different picture, but let's see.

Christopher Lilleberg
39:27 - 39:30

And is that the picture compared to previous quarters in Poland?

John Stubbington
39:31 - 39:32

Yes, I think it is.

Christopher Lilleberg
39:33 - 39:35

Okay. Great. Thank you.

John Stubbington
39:36 - 39:38

Yeah. It's there in the detail if you want to check it all.

Anand Patel
39:38 - 39:39

Thank you, Christopher.

John Stubbington
39:39 - 39:40

Thanks a lot.

Operator
39:45 - 39:49

The next question comes from Matthias from CIB. Please go ahead.

Matthias
39:51 - 40:19

Hi. Thanks for taking my questions. I'll try to zoom out a bit. The problem, or not the problem, but the softness that you mentioned in the CEO letter that you have discussed here in the presentation, isn't it really just the genetics part that obviously came through here on October 1st? Isn't that the only thing that is really new here? Yeah.

John Stubbington
40:20 - 41:06

Yes, exactly. It's true. The three things that I talked about right at the start were government contracts, property, and membership. They've been there for a while. Yeah. Of course, there are different degrees of different things that are happening. And genetics is the new one. Yeah. And of course, when you are talking about three or four things, there is a mix that we have to manage and keep an eye on. That is why we have signaled. But a lot of these things have been there for a while. Our numbers have still been good. We have managed them. But we are signaling because they are still there. And there is more. There is an extra one. So we need to see where we get to Q4. Q1.

Matthias
41:07 - 41:11

Okay. Sorry to dwell on it, but they have been there and they are not getting worse, I guess.

John Stubbington
41:12 - 41:21

Not dramatically worse. Of course, as I have said many times, we are good at managing these things. Sometimes you don't see them at all, but they're there.

Matthias
41:22 - 41:57

Perfect. Thanks. That's very clear. And I just wanted to make sure I had the same question as Christopher here, I think on Poland. So on the funded business, could you elaborate as to when this weakness or softness first appeared with the corporates? And my question was whether you see an uptick here in Q3, and if that tells us anything about the future regarding whether we are past the bottom.

John Stubbington
41:57 - 42:59

You know, our membership and our growth in the funded business are going back in time. If you go back and listen to these calls and look at the data, we've openly said that a big part of that growth came from price. We have openly said that was related to high inflation, and that the high inflation mix is starting to wash out. And maybe we kept our prices a little bit too high for a little bit too long, and we need to repurpose or make adjustments, which we've done. Yeah. As I said earlier in this call, it is B2B, which sometimes has a nine-month cycle, even when you are getting the positive signals that people are going to buy. So it takes a while to come through. Our pipeline is strong. Yeah. You still have a Q4 where there is a bit of a wash through of some of those issues. And hopefully by the time you get to next year, we will start to see us being a bit stronger in that sector. So, let's see what that pattern looks like.

Matthias
43:02 - 43:36

Thanks. That is very clear. And then on Romania, I think it is at its lowest organic revenue growth rate I can remember, disregarding the lumpiness during COVID. It has always been extremely strong. So my question here is, how much of an impact does the initiative with the limitation to greenfield expansion and contracts capped at 2025 levels have here. And I think this will remain until 2028, if I am not mistaken. Please correct me if I am wrong.

John Stubbington
43:36 - 43:37

Can you repeat the question?

Matthias
43:38 - 43:45

Yeah. Regarding the contracted beds in Romania, are they okay?

John Stubbington
43:45 - 43:49

I know what you are talking about now. Uh, okay. Yeah. I mean.

Matthias
43:50 - 43:54

That is an important factor. Or is it rather? Yeah.

John Stubbington
43:55 - 43:56

Yeah, they.

Matthias
43:56 - 44:02

I presume you can. I think you can still fill up current hospitals. Right. With more.

John Stubbington
44:02 - 44:27

Yeah. We should. That particular implication we should be able to manage. Yeah. So, we are better placed than some of our competition when it comes to that restriction. So we should be able to manage despite that restriction being in place. There are other things in the mix that are occurring. So don't be too obsessed with that particular change. From our perspective.

Matthias
44:28 - 44:41

Okay. That is clear. And then, sorry for the question. The last one is on the diagnostic services part in Romania. If you could talk about the development here in the quarter and the operating environment.

John Stubbington
44:41 - 45:13

I think the business is good. It is strong. We're still market leader and we've got great growth from the business. But of course, the economic situation that we have is a little bit tougher. And you can kind of see that, as there is a creative and very experienced team. That is why they are market leaders in their niche down there. You know, they now will do what we do: repurpose, renavigate, adjust, and look to compensate.

Matthias
45:15 - 45:16

Thank you so much.

John Stubbington
45:16 - 45:18

No problem. Thanks for the questions.

Operator
45:21 - 45:34

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Darius Saftoiu from Jefferies. Please go ahead.

Darius Saftoiu
45:36 - 46:07

Hi. Thank you for taking my questions. So just the first one, you said group organic growth, including India, was still double-digit versus Q3 8% and will continue in the business. And you've mentioned some of the seasonality impact in Q3 and some temporary headwinds, but can you discuss a bit about how we should think about the run rate into the continuing business? I appreciate not quantifying, but could you discuss some of the headwinds and drivers that were different from what you expect going forward?

Anand Patel
46:08 - 46:48

Yeah. Look, the reason I mentioned the India segment in Q3 was because at the start, John mentioned seven quarters of margin rate accretion, right? And actually, on a total basis, we've also had seven consecutive quarters of double-digit organic growth. Yes, on a total basis. Now obviously we do not expect India to be in the numbers. We hope from Q1 next year onwards. Our current run rate for Q3 is 8%. So John mentioned there may be some softening, but we are good at challenging it. So aside from that, I am not going to mention anything else in terms of giving guidance on run rates.

Darius Saftoiu
46:51 - 47:17

Yeah. Thank you. And then the second question on sports and wellness. So you mentioned you have opened four new sites in 2026 this year, and you want to expand further. So can you talk a bit about how much white space there is to expand into Poland? And also, could you comment on whether you are considering this strategy in other countries like Romania once you reach your target in Poland?

John Stubbington
47:17 - 48:23

We are very focused on Poland, so that is where we have decided to execute this particular proposition for very specific reasons. We will not declare the exact numbers we are going for, but you only have to pick up the press in Poland regarding sports wellness gyms to see that there is a lot of activity from people looking to open facilities. If you look at any trend or do any research on Western Europe regarding how many gyms per head of population there are, you will see the potential. . You will see that whilst Poland is growing really fast and strong, it is still quite a way behind the rest of Europe. Yeah. There is quite a significant space for us to move into and an increasing trend, of course, particularly with the younger generation wanting to use this type of facility. So, you know, we are not at the point where we are thinking that we have hit maturity at all.

Darius Saftoiu
48:25 - 48:49

Yeah. Thank you. And my last question. So you've mentioned you've closed 118 facilities and opened 140 in the last 12 months. So how should we think about the impact on revenue from these changes? As the new units take time to ramp up. So can you discuss a bit and provide some color on the drag on organic revenue growth from this change?

Anand Patel
48:50 - 49:39

Look, I think in the grand scheme of things, as John mentioned earlier, we have a portfolio of businesses and a portfolio of measures that are going on which adversely impact the numbers or positively impact the numbers. So I'm not going to give you a margin rate increase due to these new sites that we repurposed getting to maturity, but we expect them to step up, right? We have closed the ones we closed for the right reasons. We closed them because they were unprofitable or, as we did acquisitions, we were cannibalizing each other's sales. These were sensible financial decisions to make. The new ones that we do going forward will clearly be focused on building profitability for our business and will scale over time to hit their return on investment metrics that we set.

Darius Saftoiu
49:42 - 49:43

Thank you.

Operator
49:52 - 49:55

The next question comes from Bram Boering from Wood. Please go ahead.

Bram Boering
49:57 - 50:29

Hi, gentlemen. Sort of a broad question. There has been a lot of consolidation in the healthcare markets in Poland and Romania. How do you see the opportunities at this point for M&A growth versus organic growth, especially after proceeds from the Indian sale come in. That is one question.

Unknown 2
50:31 - 50:32

Yeah. Uh.

John Stubbington
50:32 - 52:29

We are very excited by it. Because obviously, we have funds available. We are, if you look at the environment that we are in, you have potential interest rates going up, and you have governments playing with the funds. We are a very well-placed healthcare organization because you need to look at our payer mix. We have strong fee-for-service payments, we have a strong funded payer mix, and we do have some governmental pay, which at the moment is being challenged. Yeah. But it is not the biggest. If you look at most of the organizations in our markets, it is not that kind of mix. Most of it is fund-related. If the funds are making micro changes while talking about big reforms. At the same time, interest rates and the cost of living are being challenged. Then some of the provider networks are going to struggle a little bit more with being able to cope with these kinds of things. We as a group tend to cope with it well because we are a portfolio. So when you get hit in one place, another place can help you ride that particular issue for a period of time until you correct yourself. So we think we're extremely well placed at this moment in time. Being a soon-to-be debt-free organization with those dynamics happening. And we believe further consolidation will happen. And at the same time, since the Indian deal was announced, of course, many people have been knocking on our door. So we are excited and looking forward to future quarters and future years.

Bram Boering
52:30 - 52:39

So in a nutshell, the weaker environment is creating opportunities for you to take advantage of.

John Stubbington
52:39 - 52:40

I believe so.

Bram Boering
52:42 - 52:52

Okay. And then the last question, just a small thing. The FX drag, I'm assuming, is all coming from Romania. Unless you say otherwise.

Anand Patel
52:53 - 53:04

No, but about half of it is from the zloty, so there is the zloty versus the euro as well. So, it is total zloty. And the balance is predominantly Romania as well. You are right. You are correct on Romania.

Bram Boering
53:05 - 53:10

Okay. So both countries are a drag and about equally. Thank you.

Unknown 2
53:10 - 53:11

Yeah.

Operator
53:19 - 53:27

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Unknown 2
53:28 - 53:28

Yeah.

John Stubbington
53:28 - 54:26

First and foremost, thank you, everybody, for those questions. We understand why you are asking them and it is a very interesting time for us. It is good to get those questions and be able to provide points of clarity related to the business. As you can see, we have had a very good quarter, the seventh quarter if you look at it in OldCo, of double-digit organic growth and year-on-year margin improvement. That consistency is something that we said that we would look to achieve. And it's something that we've definitely delivered. And congratulations and thank you to all of our teams for the hard work they have put in to be able to deliver that. We are looking forward to the next few quarters. And, of course, for what will happen to the shape of our business in the years to come. It is an exciting time for Medicover. So, watch this space and speak to you all soon. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…